Whitehawk Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Whitehawk Therapeutics, Inc. on June 11, 2026. The filing details the voting results for three proposals submitted to security holders. As of the record date (April 17, 2026), 40,375,023 shares were present, representing approximately 82% of the voting power, establishing a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following proposals were voted upon and approved by the stockholders:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2029 Annual Meeting.
- Behzad Aghazadeh, Ph.D.: 26,666,124 For; 5,867,225 Withheld.
- Richard Maroun: 27,701,332 For; 4,832,017 Withheld.
- Emma Reeve: 27,704,564 For; 4,828,785 Withheld.
- Proposal 2 (Executive Compensation): Advisory approval of named executive officer compensation.
- For: 22,896,061
- Against: 6,013,600
- Abstentions: 3,623,688
- Proposal 3 (Auditor Ratification): Ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 34,795,850
- Against: 1,148,282
- Abstentions: 4,430,891
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting results.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 28, 2026, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the total number of outstanding shares as of the record date to contextualize the 82% participation rate.
- Review the upcoming 10-K or 10-Q filings for the fiscal year ending December 31, 2026, to obtain financial metrics not included in this 8-K.
- Monitor the company's pipeline updates, as this filing contains no operational or clinical development data.